论文部分内容阅读
更好地了解在体内Ⅰ型人免疫缺陷病毒(HIV-1)复制的动力学就能对早期和开展强效的治疗提供很重要的依据。抗逆转录病毒联合疗法的问世,使抑制感染者的HIV-1的复制成为可能,病毒被抑制的程度可达到在血浆内2年以上再也不能检出病毒。这是在此病流行的历史上,首次从感染者体内清除HIV-1成为真正的科学目标。然而,在一段长时间内,在剩下的记忆CD_4淋巴细胞内,显然已潜伏着有复制能力的病毒存在,使完全清除HIV-1遇到极大障碍。此外,HIV-1潜伏的贮主在感染的早期就已存在并持续至表面看来有效的抗逆转录病毒联合疗法2年之后,即使在感染的初期阶段立即开展治疗也如此。然而,对潜伏HIV的贮主多少及范围还不能做出正确的评估,除非知道病毒的复制是否已被药物完全抑制。另一说法是如果不掌握HIV-1残余的复制情况,就会过高估计潜伏HIV贮主的规模。
A better understanding of the kinetics of in vivo replication of human immunodeficiency virus type 1 (HIV-1) provides an important basis for early and aggressive treatment. The advent of antiretroviral combination therapies make it possible to suppress the replication of HIV-1 in infected individuals and the extent to which the virus is inhibited can no longer be detected in the plasma for more than two years. This is the real scientific goal of clearing HIV-1 for the first time in an infected person’s history in the endemic history of the disease. However, for some time, the presence of replication competent virus has apparently lurked in the remaining memory CD 4 lymphocytes, leaving a major hurdle to completely eradicate HIV-1. In addition, latent HIV-1 reservoirs persisted in the early stages of infection and persisted to 2 months after the seemingly effective antiretroviral combination therapy was administered, even immediately after the initial stages of infection. However, it is not possible to make a correct assessment of the extent and extent of latent HIV stockpile unless it is known whether viral replication has been completely inhibited by the drug. The other argument is that if you do not know the residual copy of HIV-1, you will overestimate the size of the potential HIV reservoir.